Chemical Property of Filgrastim(granulocytecolony)
Edit
Chemical Property:
- Purity/Quality:
-
98%,99%, *data from raw suppliers
Granulocyte Colony Stimulating Factor *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
-
Biological functions
G-CSF stimulates the proliferation, differentiation, and
survival of neutrophil precursors in the bone marrow to
promote their maturation process. G-CSF exerts minimal
direct effects on the production of hematopoietic cell types
other than the neutrophil lineage, as obtained in white
blood cell differentials during clinical trials. The G-CSF-G-CSFR signaling in mature neutrophils activates multiple
effector functions in response to bacterial infections, such
as superoxide anion generation, the release of arachidonic
acid, and the production of leukocyte alkaline phosphatase and myeloperoxidase. Neurons of the CNS express
both G-CSF and G-CSF-R, suggesting an autocrine neuroprotection system, as a nonhematopoietic function
-
Description
Granulocyte colony-stimulating factor is the primary regulator of proliferation and differentiation, maturation, survival, and functions of neutrophils/
granulocytes to exert biological defense mechanisms via neutrophil progenitors in the bone marrow. The bone marrow colony-forming activity of maturing
granulocytes was recognized in various cell and tissue cultures. Murine G-CSF was first purified from a lungconditioned medium from mice injected with bacterial
endotoxin. The human G-CSF was purified from the conditioned media of tumor cell lines, and the cDNA was independently cloned in 1986 by two groups.
-
Clinical Use
Recombinant G-CSF therapies by filgrastim and lenograstim have been established in several indications. Primarily, G-CSF is administered to patients with severe
congenital or chronic neutropenia caused by a myeloid
maturation arrest in the bone marrow. G-CSF is also applicable to therapy-induced neutropenia developed in
cancer patients receiving myelosuppressive chemotherapy
and bone marrow transplant and in patients with acute
myeloid leukemia receiving induction or consolidation
chemotherapy. In addition, G-CSF induces the release of
hematopoietic stem and progenitor cells from the bone
marrow into the peripheral blood. Therefore, G-CSF is
used in transplantation therapy for the mobilization and
isolation of peripheral hematopoietic stem cells. The stem
cell mobilization by G-CSF is supported by multiple mechanisms, including proteolytic enzyme release, the modulation of adhesion molecules, and the activation of CXCR4
chemokine receptors. Recently, the nonhemopoietic role
of G-CSF has been evaluated in clinical trials including spinal cord injury by the ability of G-CSF for neuroprotective
and neuroregenerative actions.